MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO™ (fluralaner)
Dateline City:
SUMMIT, N.J.
New Chewable Tablet Treatment for Fleas and Ticks in Dogs – Effective For 12 Weeks (8 weeks for Rhipicephalus sanguineus ticks)
SUMMIT, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and
Canada) today announced that the Committee for Medicinal Products for
Veterinary Use (CVMP) of the European Medicines Agency has adopted a
positive opinion, recommending the granting of a marketing authorization
for the veterinary medicinal product BRAVECTO™ (fluralaner) chewable
tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg).
Language:
English
Contact:
MSD Animal HealthAmy Firsching, +1 908 473 6357amy.firsching@merck.comorPam Eisele, +1 908 423 5042pamela_eisele@merck.com
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News Source Type: news
More News: European Medicines Agency (EMA) | Health | Marketing | Merck | Pharmaceuticals | Veterinary Research